ESR1 and prostate carcinoma: Examples of clinical trials in NURSA 3.0 include those for: (i) breast, ovarian or prostate cancers that have been mapped to androgen receptor (AR), estrogen receptor α (ER α) or progesterone receptor (PR); (ii) treatment of chronic obstructive pulmonary diseases using the anti-inflammatory drug fluticasone, a glucocorticoid receptor (GR) agonist; and (iii) treatment of polycystic ovary syndrome (PCOS) that has been linked in OMIM, for example, to AR and ER.